10-Q: BioForce Nanosciences Q1 2026: No Revenue, Focus on New Model

BioForce Nanosciences Holdings, Inc. reported zero revenue for the first quarter of 2026, continuing its transition to a nutritional supplement business while facing ongoing operational challenges and a going concern warning.

Summary

• BioForce Nanosciences Holdings, Inc. reported no sales revenue for the first quarter ended March 31, 2026, similar to the same period in 2025.
• Operating expenses decreased to $117,733 in Q1 2026 from $133,455 in Q1 2025, primarily due to lower general and administrative expenses.
• The net loss for Q1 2026 was $102,411, a significant improvement from the $935,457 net loss in Q1 2025, partly due to a legal settlement received in the current quarter.
• The company's cash position increased to $6,347 as of March 31, 2026, from $786 as of December 31, 2025.
• The company continues to operate under a going concern warning due to recurring losses and net current liabilities, with management relying on future financing and business plan implementation for continued operations.
• A significant event in Q1 2025 involved the issuance of 4,250,000 shares of common stock to Mr. Merle Ferguson to settle accrued compensation and liabilities totaling $2,173,000, resulting in an $802,000 loss on liability settlement.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the complete lack of revenue, ongoing going concern issues, and identified material weaknesses in internal controls, despite a reduced net loss.

Positives

• Net loss significantly reduced to $102,411 in Q1 2026 from $935,457 in Q1 2025.
• Receipt of a $15,322 legal settlement in Q1 2026 contributed to the reduced net loss.
• Cash balance increased to $6,347 from $786.
• Operating expenses decreased by approximately 11.8% to $117,733 in Q1 2026 compared to $133,455 in Q1 2025.

Negatives

• Zero sales revenue reported for the first quarter of 2026, indicating no commercial traction for the nutritional supplement business.
• The company continues to face substantial doubt regarding its ability to continue as a going concern due to recurring losses and a significant accumulated deficit.
• The company has a working capital deficit of $720,954 as of March 31, 2026.
• Management acknowledges that without additional capital, the company may have to cease operations or substantially change its business plan.
• Material weaknesses were identified in internal control over financial reporting, including inadequate segregation of duties and a lack of review in the financial reporting process.

Risks

• The company's ability to continue as a going concern is dependent on its ability to implement its business plan, generate revenues, and secure additional financing.
• The company has a history of recurring losses and a substantial accumulated deficit, raising doubts about its long-term viability.
• Inadequate internal controls over financial reporting could lead to material misstatements in financial statements.
• The company's reliance on officers to pay for expenses through loans if the legal settlement funds are depleted.
• The transition to a new business model in nutritional supplements has not yet generated revenue.

Future Outlook

The company's future success is dependent on its ability to implement its business plan, expand its marketing campaign, generate revenues, and secure additional capital. Management believes its strategy to generate revenues and raise funds provides an opportunity to continue as a going concern, but there can be no assurances.

Management Comments

• Management believes that the actions presently being taken to further implement the Companys business plan; to expand sales with a dynamic marketing campaign and generate revenues provide the opportunity for the Company to continue as a going concern.
• While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect.
• Unless the Company is able to raise working capital, it is likely that the Company will either have to cease operations or substantially change its methods of operations or change its business plan.

Industry Context

StockSavvy.ai notes that BioForce Nanosciences Holdings is attempting a pivot from a failed technology business to the nutritional supplement market. This sector is highly competitive, with established players and a growing demand for health and wellness products. However, the company's current lack of revenue and significant accumulated deficit, coupled with identified material weaknesses in internal controls, present substantial hurdles to achieving success in this new venture.

Comparison to Industry Standards

• The company's reported zero revenue for the quarter is significantly below industry standards for companies operating in the nutritional supplement market, where even early-stage companies typically show some level of sales.
• The substantial accumulated deficit of over $162 million is a critical concern when compared to industry benchmarks, where companies with such a deficit and no revenue are often considered high-risk.
• The identified material weaknesses in internal controls, including inadequate segregation of duties and lack of review, are not in line with the robust financial reporting standards expected of publicly traded companies, especially those seeking to attract investment.

Corporate Governance

Legal Proceedings

• There are no material pending legal proceedings to which the Company is a party, or as to which any of its property and products are subject, and no such proceedings are known to the Company to be threatened or contemplated against it.

Related Party Transactions

• The company utilizes services from Yes International Inc., controlled by Board member Richard Kaiser, at no cost except for press release wire services and filing fees.
• The company operates out of Yes International Inc.'s offices at no cost.
• In Q1 2025, two board members paid expenses for the company totaling $3,152.
• In Q1 2025, Mr. Merle Ferguson was issued 4,250,000 shares of common stock to settle $2,173,000 in accrued compensation and liabilities.
• Mr. Ferguson also loaned $51,000 to the company in 2025.
• A shareholder loaned $10,000 in 2025, which was converted in April 2026.
• In Q1 2026, $1,527 was repaid to related parties.
• Due to related parties was $99,763 at March 31, 2026.
• In April 2026, Nauri Dean Ahmad converted a $10,000 loan into $11,000 principal and interest plus 3,000 restricted shares, receiving 24,250 shares.
• In April 2026, Merle Ferguson, a director, sold his controlling stock interest (approx. 80%) to Nexus Capital Investments, Inc.
• In May 2026, a related party advanced $13,000 for operational and professional service expenses.

Stakeholder Impact

• Shareholders: Continued lack of revenue and going concern status pose significant risks to shareholder value. Recent stock issuances and director stock sales may impact ownership structure.
• Creditors: The company's financial instability and going concern warning may impact its ability to meet its obligations.
• Employees: Uncertainty surrounding operations and potential cessation of business could impact employment.
• Management/Directors: Continued compensation accruals and related party transactions warrant scrutiny. Recent sale of controlling interest by a director may signal strategic shifts.

Next Steps

• Implement a dynamic marketing campaign to achieve brand awareness and drive business growth.
• Expand marketing efforts with a direct marketing and B2B sales campaign.
• Approach retail stores, including health food and sporting goods stores, to create vendor relationships.
• Advance social media platform with direct online and targeted advertisements.
• Continue to seek opportunities to source product in a more cost-effective way without diminished quality.

Key Dates

Recommendation

The company has zero revenue, a significant accumulated deficit, and faces substantial doubt regarding its ability to continue as a going concern. Identified material weaknesses in internal controls further exacerbate the risk. Despite a reduced net loss, the fundamental business model has not yet demonstrated any commercial viability, making it a highly speculative investment.

Keywords

BioForce Nanosciences Holdings, Form 10-Q, Quarterly Report, Nutritional Supplements, Going Concern, Financial Statements, Net Loss, Operating Expenses, SEC Filing, Nevada